CD274 and neoplasm: ICER values were below the WTP threshold for most subgroups, in line with the results of the base case analysis, emphasizing that tislelizumab plus chemotherapy represents a cost-effective treatment option irrespective of EBV DNA level, PD-L1 expression levels in tumor cells, and liver metastases at baseline in patients.